Literature DB >> 6424398

Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy.

T Keränen, J Sivenius.   

Abstract

Side effects of carbamazepine (CBZ), valproate (VPA) and clonazepam (CZP) are rare during long-term use but rather common and usually transient during the early phases of treatment. The usual side effects of CBZ are drowsiness, dizziness, and diplopia, which are dose dependent in long-term use, but CBZ does not seem to cause cognitive disturbances, as do phenobarbital and phenytoin. Other reactions to CBZ may include leukopenia, hyponatremia, disturbances of vitamin D metabolism and fortunately rarely, agranulocytosis and hepatitis. Use of VPA can lead to gastrointestinal discomfort, weight gain, hair loss, tremor and sedation, but these side effects are rather uncommon, mild, and transient during VPA monotherapy. Potentially hazardous reactions such as hepatitis and pancreatitis have occurred in a few patients on VPA, generally with multidrug therapy. Some of the side effects are dose related. They infrequently lead to withdrawal of VPA. Side effects limited to initiation of CZP therapy include drowsiness, ataxia, and behavioral changes; they are usually transient but can lead to dose reduction or even withdrawal of the drug. Except for development of tolerance, CZP seems to be practically free of long-term side effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6424398     DOI: 10.1111/j.1600-0404.1983.tb01536.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  11 in total

Review 1.  Clonazepam monotherapy for treating people with newly diagnosed epilepsy.

Authors:  Francesco Brigo; Stanley C Igwe; Nicola Luigi Bragazzi; Simona Lattanzi
Journal:  Cochrane Database Syst Rev       Date:  2022-02-21

Review 2.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.

Authors:  Victor Biton; Bassel F Shneker; Dean Naritoku; Anne E Hammer; Alain Vuong; Paul T Caldwell; John A Messenheimer
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

4.  Epileptic seizure disorders. Developments in diagnosis and therapy.

Authors:  E Niedermeyer; W Froescher; R S Fisher
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

5.  A case of syndrome of inappropriate scretion of anti-diuretic hormone associated with sodium valproate.

Authors:  Hong Joo Lee; Jung Kook Wi; Ju Young Moon; Kyung Hwan Jeong; Chun Gyoo Ihm; Sang Ho Lee; Tae Won Lee
Journal:  Electrolyte Blood Press       Date:  2012-12-31

6.  Effects of clobazam and clonazepam on saccadic eye movements and other parameters of psychomotor performance.

Authors:  C H van der Meyden; P R Bartel; D K Sommers; M Blom; L C Pretorius
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Clonazepam monotherapy for treating people with newly diagnosed epilepsy.

Authors:  Francesco Brigo; Stanley C Igwe; Nicola Luigi Bragazzi; Simona Lattanzi
Journal:  Cochrane Database Syst Rev       Date:  2019-11-19

8.  Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures.

Authors:  Swaroop Hassan Suresh; Ananya Chakraborty; Akash Virupakshaiah; Nithin Kumar
Journal:  Epilepsy Res Treat       Date:  2015-12-20

Review 9.  Recent Medico-Legal Developments on the Issue of Epilepsy and Driver's License Requirements in the Italian and European Legislation.

Authors:  Brenno Mazzariol; Antonella Pastorini; Alessandro di Luca; Natale Mario di Luca
Journal:  Behav Neurol       Date:  2019-09-30       Impact factor: 3.342

10.  Stabilization Beyond Mood: Stabilizing Patients With Bipolar Disorder in the Various Phases of Life.

Authors:  Alessio Simonetti; Alexia E Koukopoulos; Georgios D Kotzalidis; Delfina Janiri; Lavinia De Chiara; Luigi Janiri; Gabriele Sani
Journal:  Front Psychiatry       Date:  2020-04-27       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.